YU55899A - Cox-2 selective carprofen for treating pain and inflammation in dogs - Google Patents

Cox-2 selective carprofen for treating pain and inflammation in dogs

Info

Publication number
YU55899A
YU55899A YU55899A YU55899A YU55899A YU 55899 A YU55899 A YU 55899A YU 55899 A YU55899 A YU 55899A YU 55899 A YU55899 A YU 55899A YU 55899 A YU55899 A YU 55899A
Authority
YU
Yugoslavia
Prior art keywords
cox
activity
acids
dogs
inhibition
Prior art date
Application number
YU55899A
Other languages
Serbo-Croatian (sh)
Inventor
Kristin Marie Lundy
Anthony Paul Ricketts
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU55899A publication Critical patent/YU55899A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Treating or preventing inflammatory processes and diseases in dogs associated with the activity of inducible cyclo-oxygenase-2 (COX-2), while at the same time reducing or eliminating undesirable side effects associated with simultaneous inhibition of the activity of constitutive cyclo-oxygenase-1 (COX-1) by selectively inhibiting COX-2 activity with reference to COX-1 activity, wherein the selectivity ratio or COX-2 : COX-1 activity inhibition is at least 3 : 1 based on ex vivo inhibition levels measured in whole blood; the inhibitor is a member selected from the group of anti-inflammatory compounds consisting essentially of salicylic acid derivatives, p- aminophenol derivatives, indole and indene acetic acids, heteroaryl acetic acids, arylpropionic acids, anthranilic acids, enolic acids, and alkanones; the inhibitor in particular is comprised of (+)(S)-enantiomer of 6-chloro-'alpha'-methyl-9H-carbazole-2-acetic acid.
YU55899A 1997-05-05 1998-05-01 Cox-2 selective carprofen for treating pain and inflammation in dogs YU55899A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4563597P 1997-05-05 1997-05-05

Publications (1)

Publication Number Publication Date
YU55899A true YU55899A (en) 2003-08-29

Family

ID=21939053

Family Applications (1)

Application Number Title Priority Date Filing Date
YU55899A YU55899A (en) 1997-05-05 1998-05-01 Cox-2 selective carprofen for treating pain and inflammation in dogs

Country Status (32)

Country Link
EP (1) EP0988034A1 (en)
JP (1) JP2000513020A (en)
KR (2) KR20010012300A (en)
CN (1) CN1255059A (en)
AP (1) AP9801234A0 (en)
AR (2) AR011726A1 (en)
AU (1) AU6932198A (en)
BG (1) BG103852A (en)
BR (1) BR9808720A (en)
CA (1) CA2288759A1 (en)
DZ (1) DZ2479A1 (en)
EA (1) EA003696B1 (en)
GT (1) GT199800063A (en)
HR (1) HRP980244A2 (en)
HU (1) HUP0001286A3 (en)
ID (1) ID21311A (en)
IL (1) IL132570A0 (en)
IS (1) IS5220A (en)
MA (1) MA26491A1 (en)
NO (1) NO995389L (en)
NZ (1) NZ500183A (en)
OA (1) OA11213A (en)
PA (1) PA8450601A1 (en)
PE (1) PE72599A1 (en)
PL (1) PL337003A1 (en)
SK (1) SK148199A3 (en)
TN (1) TNSN98059A1 (en)
TW (1) TW590773B (en)
UY (1) UY24989A1 (en)
WO (1) WO1998050033A1 (en)
YU (1) YU55899A (en)
ZA (1) ZA983722B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245797B1 (en) 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
AU2003204888B2 (en) * 1998-05-22 2005-07-28 Pfizer Products Inc. Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives
US6506785B2 (en) * 1998-05-22 2003-01-14 Pfizer, Inc. Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
CA2347365A1 (en) * 1998-10-23 2000-05-04 Merck Frosst Canada & Co. Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use
DE60023119T2 (en) * 1999-03-10 2006-07-20 G.D. Searle Llc COMPOSITIONS FOR THE ADMINISTRATION OF A CYCLOOXYGENASE-2 HEMMER TO ANIMALS
WO2001034204A1 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001087343A2 (en) * 2000-05-15 2001-11-22 Merck Frosst Canada & Co. Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
PL206268B1 (en) 2000-06-13 2010-07-30 Wyethwyeth Analgesic and anti-inflammatory compositions containing cox-2 inhibitors
DE10032132A1 (en) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermal therapeutic system containing non-steroidal anti-inflammatory drugs with selective COX-2 inhibition
EP1307585B1 (en) 2000-08-07 2009-01-21 Vanderbilt University Compositions and methods for detecting and quantifying cox-2 activity and 2-arachidonylglycerol metabolites
WO2003007875A2 (en) * 2001-07-16 2003-01-30 Hoegestaett Edward Compounds with analgesic, antipyretic and/or anti-inflammatory activity
ES2275218T3 (en) 2003-05-07 2007-06-01 Osteologix A/S HYDROSOLUBLE STRONTIUM SALTS FOR THE TREATMENT OF CARTILAGOS AND / OR BONE AFFECTIONS.
MXPA06001288A (en) * 2003-07-31 2006-04-11 Upjohn Co Dispersible formulation of an anti-inflammatory agent.
EA200702280A1 (en) * 2005-05-20 2008-04-28 Пфайзер Лимитед SYNERGISTIC COMBINATIONS
JP2010523554A (en) 2007-04-04 2010-07-15 シグモイド・ファーマ・リミテッド Pharmaceutical composition of tacrolimus
US8951570B2 (en) 2007-04-26 2015-02-10 Sigmoid Pharma Limited Manufacture of multiple minicapsules
GB2483815B (en) 2009-05-18 2013-12-25 Sigmoid Pharma Ltd Composition comprising oil drops
CN107582526A (en) 2009-08-12 2018-01-16 希格默伊德药业有限公司 Immune regulation composite comprising polymer substrate and oil phase
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CN105939713A (en) 2014-03-06 2016-09-14 阿莱塔纳治疗学股份有限公司 Compositions of grapiprant and methods for using same
AU2015341695B2 (en) 2014-11-07 2021-07-08 Sublimity Therapeutics Limited Compositions comprising cyclosporin
WO2016112312A1 (en) * 2015-01-09 2016-07-14 Jaguar Animal Health Methods of treating diarrhea in companion animals
WO2021195346A1 (en) * 2020-03-25 2021-09-30 Sri International Lipoxygenase inhibitors
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
KR102404883B1 (en) 2020-11-30 2022-06-07 (주)이노보테라퓨틱스 Pharmaceutical composition for preventing or treating keloid or hypertrophic scar comprising Benzbromarone

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896145A (en) * 1972-07-24 1975-07-22 Hoffmann La Roche Carbazoles
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions

Also Published As

Publication number Publication date
HUP0001286A2 (en) 2000-11-28
GT199800063A (en) 1999-10-26
CA2288759A1 (en) 1998-11-12
WO1998050033A1 (en) 1998-11-12
PL337003A1 (en) 2000-07-31
EA199900895A1 (en) 2000-06-26
NZ500183A (en) 2002-04-26
ZA983722B (en) 1999-11-04
KR20010012300A (en) 2001-02-15
DZ2479A1 (en) 2003-02-01
AR011726A1 (en) 2000-08-30
AP9801234A0 (en) 1999-11-04
PE72599A1 (en) 1999-08-12
PA8450601A1 (en) 2000-05-24
MA26491A1 (en) 2004-12-20
NO995389D0 (en) 1999-11-04
EA003696B1 (en) 2003-08-28
OA11213A (en) 2003-07-14
SK148199A3 (en) 2001-09-11
IS5220A (en) 1999-10-19
AR039628A2 (en) 2005-03-02
KR20040004406A (en) 2004-01-13
UY24989A1 (en) 2001-10-25
AU6932198A (en) 1998-11-27
HUP0001286A3 (en) 2000-12-28
CN1255059A (en) 2000-05-31
TW590773B (en) 2004-06-11
EP0988034A1 (en) 2000-03-29
NO995389L (en) 2000-01-04
ID21311A (en) 1999-05-20
HRP980244A2 (en) 1999-02-28
JP2000513020A (en) 2000-10-03
BG103852A (en) 2000-06-30
BR9808720A (en) 2000-07-11
IL132570A0 (en) 2001-03-19
TNSN98059A1 (en) 2005-03-15

Similar Documents

Publication Publication Date Title
YU55899A (en) Cox-2 selective carprofen for treating pain and inflammation in dogs
NO2006007I1 (en) (+) - (S) -2- (3-benzoylphenyl) propionic acid tromethamine salt (deksketoprofentrometamol)
MY106628A (en) Estrogen-containing active substance plaster
NZ330860A (en) Method of inhibiting photoaging of skin
NO985575L (en) Methods and Preparations Useful for Inhibiting <alfa> v <beta> 5-Mediated Angiogenesis
DE69613840D1 (en) ORAL DOSAGE FORM AND METHOD FOR TREATING PAIN CONDITIONS IN THE ORAL CAVE
TR200201920T2 (en) Carboxylic acid derivatives that inhibit the binding of integrins to their receptors.
PT1039895E (en) USE OF RESPECTIVE ESTER OR AMID 3-BENZOYLPHENYL ACID ACIDS FOR THE TREATMENT OF GLC1A GLAUCOMA
NO20002440D0 (en) Hydroxamic and carboxylic acid derivatives with MMP and TNF inhibitory activity
ATE333874T1 (en) CONJUGATED LINOLENIC ACID FOR THE TREATMENT OF CYCLOOXYGENASE-2 MEDIATED INFLAMMATION AND PAIN
DE60014369D1 (en) PROPANIC ACID DERIVATIVES THAT INHIBIT INTEGRINE BINDING TO THEIR RECEPTORS
Umemiya et al. Action mechanism of retinoid-synergistic dibenzodiazepines
IL143594A0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
ZA978400B (en) Use of inhibitors of the activity of retinoic acid to promote healing.
Hirabayashi et al. 7-Nitroindazole attenuates nitrotyrosine formation in the early phase of cerebral ischemia-reperfusion in mice
ATE372126T1 (en) FLUSH SOLUTION AND METHOD FOR PAIN RELIEF AND ANTI-INFLAMMATORY
HUP0001097A2 (en) Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
CO5021216A1 (en) SELECTIVE CARPROPHENE FOR COX-2, FOR THE TREATMENT OF PAIN AND INFLAMMATION IN DOGS
ATE286892T1 (en) HYDROXAM AND CARBOXYLIC ACID DERIVATIVES WITH MMP AND TNF INHIBITING ACTIVITY
ATE232541T1 (en) BALE ACID SALTS WITH PHYSIOLOGICALLY ACTIVE METALS AND THEIR USE FOR THERAPEUTIC TREATMENT
TR200202103T2 (en) '' 5 - [{6- (2-Fluorobenzyl) oxy-2-naphthyl} methyl] -2,4-thiazolidine dion crystals ''
FR2760363B1 (en) COMPOSITION FOR THE TOPICAL TREATMENT OF SKIN CONDITIONS AND PHANERAS
WO2001041771A3 (en) Transdermal system containing acetylsalicylic acid for treatment of migraine
BR9813164A (en) Method of using cyclooxygenase-2 inhibitors to maintain the fetal arterial duct during treatment and prevent premature labor pains
NO960866L (en) Method of treating liver disease and similar indications with vasodilating agents